{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/TVTX/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-14T23:55:32.142Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":2905,"canonical_name":"Travere Therapeutics, Inc.","cik":"0001438533","uei":null,"lei":null,"duns":null,"ticker":"TVTX"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":101,"clinical":4},"count":100,"timeline":[{"ts":"2026-09-21","kind":"sec.filing","form_type":"8-K","title":"8-K — Travere Therapeutics, Inc. — 2026-09-21","url_slug":"/sec/cik-0001438533/8-k/0001438533-26-000068","accession_number":"0001438533-26-000068","importance":35},{"ts":"2026-09-17","kind":"sec.filing","form_type":"144","title":"144 — Travere Therapeutics, Inc. — 2026-09-17","url_slug":"/sec/cik-0001438533/144/0001950047-26-009625","accession_number":"0001950047-26-009625","importance":30},{"ts":"2026-09-17","kind":"sec.filing","form_type":"144","title":"144 — Travere Therapeutics, Inc. — 2026-09-17","url_slug":"/sec/cik-0001438533/144/0001950047-26-009642","accession_number":"0001950047-26-009642","importance":30},{"ts":"2026-09-17","kind":"sec.filing","form_type":"4","title":"4 — Travere Therapeutics, Inc. — 2026-09-17","url_slug":"/sec/cik-0001438533/4/0001698262-26-000005","accession_number":"0001698262-26-000005","importance":30},{"ts":"2026-09-17","kind":"sec.filing","form_type":"4","title":"4 — Travere Therapeutics, Inc. — 2026-09-17","url_slug":"/sec/cik-0001438533/4/0001763494-26-000007","accession_number":"0001763494-26-000007","importance":30},{"ts":"2026-09-17","kind":"sec.filing","form_type":"4","title":"4 — Travere Therapeutics, Inc. — 2026-09-17","url_slug":"/sec/cik-0001438533/4/0001789617-26-000004","accession_number":"0001789617-26-000004","importance":30},{"ts":"2026-09-17","kind":"sec.filing","form_type":"4","title":"4 — Travere Therapeutics, Inc. — 2026-09-17","url_slug":"/sec/cik-0001438533/4/0001882909-26-000004","accession_number":"0001882909-26-000004","importance":30},{"ts":"2026-09-17","kind":"sec.filing","form_type":"4","title":"4 — Travere Therapeutics, Inc. — 2026-09-17","url_slug":"/sec/cik-0001438533/4/0001902368-26-000008","accession_number":"0001902368-26-000008","importance":30},{"ts":"2026-09-17","kind":"sec.filing","form_type":"4","title":"4 — Travere Therapeutics, Inc. — 2026-09-17","url_slug":"/sec/cik-0001438533/4/0001943192-26-000006","accession_number":"0001943192-26-000006","importance":30},{"ts":"2026-09-17","kind":"sec.insider.8282","reporter":"Heerma Peter","title":"EVP, CHIEF COMMERCIAL OFFICER","shares":8282,"price_per_share":65.0709,"usd_value":538917,"security_title":"Common Stock","importance":15.5389171938},{"ts":"2026-09-17","kind":"sec.insider.8282","reporter":"Heerma Peter","title":"EVP, CHIEF COMMERCIAL OFFICER","shares":8282,"price_per_share":22.4,"usd_value":185517,"security_title":"Common Stock","importance":15.1855168},{"ts":"2026-09-16","kind":"sec.filing","form_type":"144","title":"144 — Travere Therapeutics, Inc. — 2026-09-16","url_slug":"/sec/cik-0001438533/144/0001950047-26-009566","accession_number":"0001950047-26-009566","importance":30},{"ts":"2026-09-16","kind":"sec.filing","form_type":"144","title":"144 — Travere Therapeutics, Inc. — 2026-09-16","url_slug":"/sec/cik-0001438533/144/0001950047-26-009576","accession_number":"0001950047-26-009576","importance":30},{"ts":"2026-09-16","kind":"sec.filing","form_type":"144","title":"144 — Travere Therapeutics, Inc. — 2026-09-16","url_slug":"/sec/cik-0001438533/144/0001950047-26-009577","accession_number":"0001950047-26-009577","importance":30},{"ts":"2026-09-16","kind":"sec.insider.93604","reporter":"Heerma Peter","title":"EVP, CHIEF COMMERCIAL OFFICER","shares":93604,"price_per_share":63.2471,"usd_value":5920182,"security_title":"Common Stock","importance":20.920181548400002},{"ts":"2026-09-16","kind":"sec.insider.79113","reporter":"Heerma Peter","title":"EVP, CHIEF COMMERCIAL OFFICER","shares":79113,"price_per_share":63.6546,"usd_value":5035906,"security_title":"Common Stock","importance":20.0359063698},{"ts":"2026-09-16","kind":"sec.insider.65104","reporter":"ROTE WILLIAM E.","title":"Chief Research Officer","shares":65104,"price_per_share":63.1205,"usd_value":4109397,"security_title":"Common Stock","importance":19.109397032},{"ts":"2026-09-16","kind":"sec.insider.47746","reporter":"ROTE WILLIAM E.","title":"Chief Research Officer","shares":47746,"price_per_share":63.6126,"usd_value":3037247,"security_title":"Common Stock","importance":18.0372471996},{"ts":"2026-09-16","kind":"sec.insider.57500","reporter":"ROTE WILLIAM E.","title":"Chief Research Officer","shares":57500,"price_per_share":26.88,"usd_value":1545600,"security_title":"Common Stock","importance":16.5456},{"ts":"2026-09-16","kind":"sec.insider.100000","reporter":"Heerma Peter","title":"EVP, CHIEF COMMERCIAL OFFICER","shares":100000,"price_per_share":11.25,"usd_value":1125000,"security_title":"Common Stock","importance":16.125},{"ts":"2026-09-16","kind":"sec.insider.55000","reporter":"ROTE WILLIAM E.","title":"Chief Research Officer","shares":55000,"price_per_share":15.46,"usd_value":850300,"security_title":"Common Stock","importance":15.8503},{"ts":"2026-09-16","kind":"sec.insider.55000","reporter":"Heerma Peter","title":"EVP, CHIEF COMMERCIAL OFFICER","shares":55000,"price_per_share":15.46,"usd_value":850300,"security_title":"Common Stock","importance":15.8503},{"ts":"2026-09-16","kind":"sec.insider.17717","reporter":"Heerma Peter","title":"EVP, CHIEF COMMERCIAL OFFICER","shares":17717,"price_per_share":26.88,"usd_value":476233,"security_title":"Common Stock","importance":15.47623296},{"ts":"2026-09-16","kind":"sec.insider.350","reporter":"ROTE WILLIAM E.","title":"Chief Research Officer","shares":350,"price_per_share":17.96,"usd_value":6286,"security_title":"Common Stock","importance":15.006286},{"ts":"2026-09-15","kind":"sec.filing","form_type":"144","title":"144 — Travere Therapeutics, Inc. — 2026-09-15","url_slug":"/sec/cik-0001438533/144/0001950047-26-009488","accession_number":"0001950047-26-009488","importance":30},{"ts":"2026-09-15","kind":"sec.filing","form_type":"144","title":"144 — Travere Therapeutics, Inc. — 2026-09-15","url_slug":"/sec/cik-0001438533/144/0001950047-26-009503","accession_number":"0001950047-26-009503","importance":30},{"ts":"2026-09-15","kind":"sec.filing","form_type":"144","title":"144 — Travere Therapeutics, Inc. — 2026-09-15","url_slug":"/sec/cik-0001438533/144/0001950047-26-009510","accession_number":"0001950047-26-009510","importance":30},{"ts":"2026-09-15","kind":"sec.filing","form_type":"144","title":"144 — Travere Therapeutics, Inc. — 2026-09-15","url_slug":"/sec/cik-0001438533/144/0001950047-26-009513","accession_number":"0001950047-26-009513","importance":30},{"ts":"2026-09-15","kind":"sec.filing","form_type":"144","title":"144 — Travere Therapeutics, Inc. — 2026-09-15","url_slug":"/sec/cik-0001438533/144/0001950047-26-009521","accession_number":"0001950047-26-009521","importance":30},{"ts":"2026-09-15","kind":"sec.filing","form_type":"144","title":"144 — Travere Therapeutics, Inc. — 2026-09-15","url_slug":"/sec/cik-0001438533/144/0001950047-26-009523","accession_number":"0001950047-26-009523","importance":30},{"ts":"2026-09-15","kind":"sec.insider.71938","reporter":"Heerma Peter","title":"EVP, CHIEF COMMERCIAL OFFICER","shares":71938,"price_per_share":62.0517,"usd_value":4463875,"security_title":"Common Stock","importance":19.4638751946},{"ts":"2026-09-15","kind":"sec.insider.63907","reporter":"ROTE WILLIAM E.","title":"Chief Research Officer","shares":63907,"price_per_share":61.994,"usd_value":3961851,"security_title":"Common Stock","importance":18.961850558000002},{"ts":"2026-09-15","kind":"sec.insider.29021","reporter":"ROTE WILLIAM E.","title":"Chief Research Officer","shares":29021,"price_per_share":62.6552,"usd_value":1818317,"security_title":"Common Stock","importance":16.8183165592},{"ts":"2026-09-15","kind":"sec.insider.27421","reporter":"Heerma Peter","title":"EVP, CHIEF COMMERCIAL OFFICER","shares":27421,"price_per_share":62.5936,"usd_value":1716379,"security_title":"Common Stock","importance":16.7163791056},{"ts":"2026-09-15","kind":"sec.insider.25390","reporter":"Inrig Jula","title":"EVP, Head of R&D & CMO","shares":25390,"price_per_share":62.0167,"usd_value":1574604,"security_title":"Common Stock","importance":16.574604013},{"ts":"2026-09-15","kind":"sec.insider.21926","reporter":"REED ELIZABETH E","title":"Chief Legal Officer and GC","shares":21926,"price_per_share":62.0255,"usd_value":1359971,"security_title":"Common Stock","importance":16.359971113},{"ts":"2026-09-15","kind":"sec.insider.17284","reporter":"Inrig Jula","title":"EVP, Head of R&D & CMO","shares":17284,"price_per_share":62.6242,"usd_value":1082397,"security_title":"Common Stock","importance":16.0823966728},{"ts":"2026-09-15","kind":"sec.insider.39283","reporter":"Heerma Peter","title":"EVP, CHIEF COMMERCIAL OFFICER","shares":39283,"price_per_share":26.88,"usd_value":1055927,"security_title":"Common Stock","importance":16.05592704},{"ts":"2026-09-15","kind":"sec.insider.39000","reporter":"ROTE WILLIAM E.","title":"Chief Research Officer","shares":39000,"price_per_share":25.25,"usd_value":984750,"security_title":"Common Stock","importance":15.98475},{"ts":"2026-09-15","kind":"sec.insider.13874","reporter":"REED ELIZABETH E","title":"Chief Legal Officer and GC","shares":13874,"price_per_share":62.6326,"usd_value":868965,"security_title":"Common Stock","importance":15.8689646924},{"ts":"2026-09-15","kind":"sec.insider.39650","reporter":"ROTE WILLIAM E.","title":"Chief Research Officer","shares":39650,"price_per_share":17.96,"usd_value":712114,"security_title":"Common Stock","importance":15.712114},{"ts":"2026-09-15","kind":"sec.insider.37500","reporter":"REED ELIZABETH E","title":"Chief Legal Officer and GC","shares":37500,"price_per_share":15.46,"usd_value":579750,"security_title":"Common Stock","importance":15.57975},{"ts":"2026-09-15","kind":"sec.insider.36526","reporter":"Heerma Peter","title":"EVP, CHIEF COMMERCIAL OFFICER","shares":36526,"price_per_share":8.93,"usd_value":326177,"security_title":"Common Stock","importance":15.32617718},{"ts":"2026-09-15","kind":"sec.insider.32395","reporter":"Inrig Jula","title":"EVP, Head of R&D & CMO","shares":32395,"price_per_share":8.93,"usd_value":289287,"security_title":"Common Stock","importance":15.28928735},{"ts":"2026-09-15","kind":"sec.insider.3000","reporter":"ROTE WILLIAM E.","title":"Chief Research Officer","shares":3000,"price_per_share":63.6508,"usd_value":190952,"security_title":"Common Stock","importance":15.1909524},{"ts":"2026-09-15","kind":"sec.insider.1600","reporter":"Inrig Jula","title":"EVP, Head of R&D & CMO","shares":1600,"price_per_share":63.685,"usd_value":101896,"security_title":"Common Stock","importance":15.101896},{"ts":"2026-09-15","kind":"sec.insider.1431","reporter":"Heerma Peter","title":"EVP, CHIEF COMMERCIAL OFFICER","shares":1431,"price_per_share":65.3093,"usd_value":93458,"security_title":"Common Stock","importance":15.0934576083},{"ts":"2026-09-15","kind":"sec.insider.1400","reporter":"REED ELIZABETH E","title":"Chief Legal Officer and GC","shares":1400,"price_per_share":63.6902,"usd_value":89166,"security_title":"Common Stock","importance":15.08916628},{"ts":"2026-09-15","kind":"sec.insider.1400","reporter":"Heerma Peter","title":"EVP, CHIEF COMMERCIAL OFFICER","shares":1400,"price_per_share":63.6521,"usd_value":89113,"security_title":"Common Stock","importance":15.08911294},{"ts":"2026-09-15","kind":"sec.insider.1381","reporter":"Heerma Peter","title":"EVP, CHIEF COMMERCIAL OFFICER","shares":1381,"price_per_share":22.4,"usd_value":30934,"security_title":"Common Stock","importance":15.0309344},{"ts":"2026-09-15","kind":"sec.insider.400","reporter":"Inrig Jula","title":"EVP, Head of R&D & CMO","shares":400,"price_per_share":65.31,"usd_value":26124,"security_title":"Common Stock","importance":15.026124},{"ts":"2026-09-15","kind":"sec.insider.300","reporter":"REED ELIZABETH E","title":"Chief Legal Officer and GC","shares":300,"price_per_share":65.31,"usd_value":19593,"security_title":"Common Stock","importance":15.019593},{"ts":"2026-09-15","kind":"sec.insider.270","reporter":"ROTE WILLIAM E.","title":"Chief Research Officer","shares":270,"price_per_share":65.31,"usd_value":17634,"security_title":"Common Stock","importance":15.0176337},{"ts":"2026-09-11","kind":"sec.filing","form_type":"4","title":"4 — Travere Therapeutics, Inc. — 2026-09-11","url_slug":"/sec/cik-0001438533/4/0001506916-26-000004","accession_number":"0001506916-26-000004","importance":30},{"ts":"2026-09-10","kind":"sec.insider.s","reporter":"Meckler Jeffrey A","title":"","shares":14000,"price_per_share":67.4634,"usd_value":944488,"security_title":"Common Stock","importance":35.9444876},{"ts":"2026-09-10","kind":"sec.insider.s","reporter":"Meckler Jeffrey A","title":"","shares":3100,"price_per_share":68.088,"usd_value":211073,"security_title":"Common Stock","importance":35.2110728},{"ts":"2026-09-10","kind":"sec.insider.s","reporter":"Meckler Jeffrey A","title":"","shares":1700,"price_per_share":65.3917,"usd_value":111166,"security_title":"Common Stock","importance":35.11116589},{"ts":"2026-09-10","kind":"sec.insider.s","reporter":"Meckler Jeffrey A","title":"","shares":1200,"price_per_share":66.15,"usd_value":79380,"security_title":"Common Stock","importance":35.07938},{"ts":"2026-09-10","kind":"sec.filing","form_type":"144","title":"144 — Travere Therapeutics, Inc. — 2026-09-10","url_slug":"/sec/cik-0001438533/144/0001950047-26-009292","accession_number":"0001950047-26-009292","importance":30},{"ts":"2026-09-10","kind":"sec.insider.m","reporter":"Meckler Jeffrey A","title":"","shares":10000,"price_per_share":26.52,"usd_value":265200,"security_title":"Common Stock","importance":15.2652},{"ts":"2026-09-10","kind":"sec.insider.m","reporter":"Meckler Jeffrey A","title":"","shares":10000,"price_per_share":17.44,"usd_value":174400,"security_title":"Common Stock","importance":15.1744},{"ts":"2026-09-03","kind":"sec.filing","form_type":"4","title":"4 — Travere Therapeutics, Inc. — 2026-09-03","url_slug":"/sec/cik-0001438533/4/0001943192-26-000005","accession_number":"0001943192-26-000005","importance":30},{"ts":"2026-08-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Travere Therapeutics, Inc. — 2026-08-14","url_slug":"/sec/cik-0001438533/schedule-13g-a/0001172661-26-003621","accession_number":"0001172661-26-003621","importance":30},{"ts":"2026-08-12","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Travere Therapeutics, Inc. — 2026-08-12","url_slug":"/sec/cik-0001438533/schedule-13g/0000070858-26-000437","accession_number":"0000070858-26-000437","importance":55},{"ts":"2026-08-07","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Travere Therapeutics, Inc. — 2026-08-07","url_slug":"/sec/cik-0001438533/schedule-13g/0000093751-26-000546","accession_number":"0000093751-26-000546","importance":55},{"ts":"2026-08-06","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Travere Therapeutics, Inc. — 2026-08-06","url_slug":"/sec/cik-0001438533/schedule-13g-a/0000315066-26-002183","accession_number":"0000315066-26-002183","importance":30},{"ts":"2026-08-04","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Travere Therapeutics, Inc. — 2026-08-04","url_slug":"/sec/cik-0001438533/10-q/0001438533-26-000063","accession_number":"0001438533-26-000063","importance":45},{"ts":"2026-08-04","kind":"sec.filing","form_type":"8-K","title":"8-K — Travere Therapeutics, Inc. — 2026-08-04","url_slug":"/sec/cik-0001438533/8-k/0001438533-26-000062","accession_number":"0001438533-26-000062","importance":35},{"ts":"2026-07-09","kind":"sec.filing","form_type":"8-K","title":"8-K — Travere Therapeutics, Inc. — 2026-07-09","url_slug":"/sec/cik-0001438533/8-k/0001438533-26-000054","accession_number":"0001438533-26-000054","importance":35},{"ts":"2026-06-22","kind":"sec.filing","form_type":"4","title":"4 — Travere Therapeutics, Inc. — 2026-06-22","url_slug":"/sec/cik-0001438533/4/0001902368-26-000007","accession_number":"0001902368-26-000007","importance":30},{"ts":"2026-06-22","kind":"sec.insider.g","reporter":"Inrig Jula","title":"CHIEF MEDICAL OFFICER","shares":468,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-17","kind":"sec.filing","form_type":"S-8","title":"S-8 — Travere Therapeutics, Inc. — 2026-06-17","url_slug":"/sec/cik-0001438533/s-8/0001438533-26-000052","accession_number":"0001438533-26-000052","importance":30},{"ts":"2026-06-16","kind":"sec.filing","form_type":"8-K","title":"8-K — Travere Therapeutics, Inc. — 2026-06-16","url_slug":"/sec/cik-0001438533/8-k/0001438533-26-000048","accession_number":"0001438533-26-000048","importance":35},{"ts":"2026-06-16","kind":"sec.filing","form_type":"4","title":"4 — Travere Therapeutics, Inc. — 2026-06-16","url_slug":"/sec/cik-0001438533/4/0001680739-26-000014","accession_number":"0001680739-26-000014","importance":30},{"ts":"2026-06-12","kind":"sec.form144","reporter":"Coughlin Timothy","title":"Director","shares":10000,"usd_value":500430,"security_title":"Common","approx_sale_date":"2026-06-12","accession_number":"0001376043-26-000007","importance":40.100085944},{"ts":"2026-06-12","kind":"sec.form144","reporter":"ROY BAYNES","title":"Director","shares":4500,"usd_value":225000,"security_title":"Common","approx_sale_date":"2026-06-12","accession_number":"0001950047-26-005979","importance":40.045},{"ts":"2026-06-12","kind":"sec.insider.s","reporter":"Coughlin Timothy","title":"","shares":10000,"price_per_share":50.0747,"usd_value":500747,"security_title":"Common Stock","importance":35.500747},{"ts":"2026-06-12","kind":"sec.insider.s","reporter":"Baynes Roy D.","title":"","shares":4500,"price_per_share":50,"usd_value":225000,"security_title":"Common Stock","importance":35.225},{"ts":"2026-06-12","kind":"sec.filing","form_type":"144","title":"144 — Travere Therapeutics, Inc. — 2026-06-12","url_slug":"/sec/cik-0001438533/144/0001950047-26-005979","accession_number":"0001950047-26-005979","importance":30},{"ts":"2026-06-12","kind":"sec.insider.m","reporter":"Coughlin Timothy","title":"","shares":10000,"price_per_share":26.52,"usd_value":265200,"security_title":"Common Stock","importance":15.2652},{"ts":"2026-06-12","kind":"sec.insider.m","reporter":"Baynes Roy D.","title":"","shares":4500,"price_per_share":21.38,"usd_value":96210,"security_title":"Common Stock","importance":15.09621},{"ts":"2026-06-02","kind":"sec.filing","form_type":"8-K","title":"8-K — Travere Therapeutics, Inc. — 2026-06-02","url_slug":"/sec/cik-0001438533/8-k/0001193125-26-252474","accession_number":"0001193125-26-252474","importance":35},{"ts":"2026-05-21","kind":"sec.filing","form_type":"8-K","title":"8-K — Travere Therapeutics, Inc. — 2026-05-21","url_slug":"/sec/cik-0001438533/8-k/0001438533-26-000046","accession_number":"0001438533-26-000046","importance":35},{"ts":"2026-05-21","kind":"sec.filing","form_type":"4","title":"4 — Travere Therapeutics, Inc. — 2026-05-21","url_slug":"/sec/cik-0001438533/4/0001454001-26-000002","accession_number":"0001454001-26-000002","importance":30},{"ts":"2026-05-21","kind":"sec.filing","form_type":"4","title":"4 — Travere Therapeutics, Inc. — 2026-05-21","url_slug":"/sec/cik-0001438533/4/0001477384-26-000008","accession_number":"0001477384-26-000008","importance":30},{"ts":"2026-05-21","kind":"sec.filing","form_type":"4","title":"4 — Travere Therapeutics, Inc. — 2026-05-21","url_slug":"/sec/cik-0001438533/4/0001506916-26-000003","accession_number":"0001506916-26-000003","importance":30},{"ts":"2026-05-21","kind":"sec.filing","form_type":"4","title":"4 — Travere Therapeutics, Inc. — 2026-05-21","url_slug":"/sec/cik-0001438533/4/0001517790-26-000002","accession_number":"0001517790-26-000002","importance":30},{"ts":"2026-05-21","kind":"sec.filing","form_type":"4","title":"4 — Travere Therapeutics, Inc. — 2026-05-21","url_slug":"/sec/cik-0001438533/4/0001619622-26-000002","accession_number":"0001619622-26-000002","importance":30},{"ts":"2026-05-21","kind":"sec.filing","form_type":"4","title":"4 — Travere Therapeutics, Inc. — 2026-05-21","url_slug":"/sec/cik-0001438533/4/0001680739-26-000012","accession_number":"0001680739-26-000012","importance":30},{"ts":"2026-05-19","kind":"sec.insider.a","reporter":"LYONS GARY A","title":"","shares":4000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-19","kind":"sec.insider.a","reporter":"Williams Brinkley Ruth","title":"","shares":4000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-19","kind":"sec.insider.a","reporter":"Coughlin Timothy","title":"","shares":4000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-19","kind":"sec.insider.a","reporter":"Squarer Ron","title":"","shares":4000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-19","kind":"sec.insider.a","reporter":"Orwin John A","title":"","shares":4000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-19","kind":"sec.insider.a","reporter":"Meckler Jeffrey A","title":"","shares":4000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-19","kind":"sec.insider.a","reporter":"Bruhn Suzanne Louise","title":"","shares":4000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-19","kind":"sec.insider.a","reporter":"Poole Sandra","title":"","shares":4000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-19","kind":"sec.insider.a","reporter":"Baynes Roy D.","title":"","shares":4000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Travere Therapeutics, Inc. — 2026-05-15","url_slug":"/sec/cik-0001438533/schedule-13g/0001172661-26-002146","accession_number":"0001172661-26-002146","importance":55},{"ts":"2026-05-15","kind":"sec.form144","reporter":"Coughlin Timothy","title":"Director","shares":3250,"usd_value":141183,"security_title":"Common","approx_sale_date":"2026-05-15","accession_number":"0001376043-26-000004","importance":40.028236518}]}